The vaccine college students are skipping is the meningococcal serogroup B vaccine, known as MenB, and the consequences range from permanent brain damage to death. While 26 states require the MenACWY vaccine for college entry, only 2 states mandate the MenB shot — the very one that targets the serogroup responsible for every single college meningococcal outbreak from 2011 through March 2019. During that stretch, 13 campuses saw 50 cases and 2 student deaths among roughly 253,000 students. Parents who believe their child is “fully vaccinated for meningitis” before move-in day are almost certainly wrong, and the gap between assumption and reality is where tragedy lives. This matters profoundly for brain health. Meningococcal meningitis is an infection of the membranes surrounding the brain and spinal cord, and its neurological fallout — seizures, cognitive impairment, hearing loss — can be permanent.
Up to 20 percent of survivors carry lifelong complications, according to the World Health Organization and the National Foundation for Infectious Diseases. For a generation of young people whose brains are still developing, skipping a vaccine that costs a few hundred dollars can mean paying with decades of diminished neurological function. This article covers why the MenB gap exists, who is most at risk, what the rising case numbers mean, and what new vaccine options could finally close the gap. The brain health implications deserve particular attention. When bacterial meningitis damages the meninges, the inflammation can destroy neurons, impair blood flow to critical brain regions, and leave survivors with epilepsy, memory deficits, and personality changes that resemble early-onset cognitive decline. Some survivors require the same rehabilitative care pathways as traumatic brain injury patients. Understanding this vaccine gap is not just a public health story — it is a brain health story with consequences that can last a lifetime.
Table of Contents
- Why Do Most College Students Miss the MenB Meningitis Vaccine?
- The Neurological Damage Meningococcal Meningitis Leaves Behind
- Rising Case Counts Signal a Growing Threat
- What Parents and Students Should Actually Do Before Move-In Day
- The Limitation of Mandates and the Problem of Awareness
- Pentavalent Vaccines Could Change the Equation
- What the Future Holds for Meningitis Prevention on Campus
- Conclusion
- Frequently Asked Questions
Why Do Most College Students Miss the MenB Meningitis Vaccine?
The answer is deceptively simple: nobody requires them to get it. MenACWY vaccination, which covers serogroups A, C, W, and Y, is mandated in 26 states for college enrollment. Coverage among 17-year-olds sits at an impressive 90.7 percent for at least one dose. But the MenB vaccine, which covers serogroup B — the strain behind 63 to 67 percent of meningococcal cases in college-aged students from 2019 to 2021, according to CDC surveillance data — has coverage below 30 percent for even one dose and under 20 percent for the full series, based on 2022 national survey data. The disparity is staggering, and it is not accidental. MenB carries only a “Category B” recommendation from the Advisory Committee on Immunization Practices, meaning it is suggested through shared clinical decision-making rather than universally recommended. In practice, that means most pediatricians mention it in passing, if at all. The data from 2015 to 2018 illustrates the gap with uncomfortable clarity.
Between 90 and 100 percent of college students who contracted meningococcal disease during that period had received the MenACWY vaccine. Only 0 to 14 percent had received MenB. These students and their families did everything they thought was right. They followed the school’s requirements, checked the boxes on the health forms, and still ended up in intensive care because no one told them there was another vaccine they needed. Johns Hopkins Medicine has specifically warned parents that the MenB vaccine is the one most likely to be missed before college because it is not required in most states. The distinction matters because serogroup B behaves differently on college campuses than other serogroups. The close-quarters living arrangements in dormitories, shared dining halls, and the social behaviors common among 18-to-22-year-olds create ideal conditions for bacterial transmission. MenB is not just slightly more common in this population — it dominates. When a campus outbreak makes the news, it is almost always serogroup B, and the students who thought they were protected discover they were only half-protected.
The Neurological Damage Meningococcal Meningitis Leaves Behind
Roughly 1 in 10 people who contract meningococcal disease will die, often within 24 to 48 hours of symptom onset. But the survivors’ stories are in many ways harder to reckon with. Up to 20 percent of those who survive suffer permanent complications that include hearing loss, seizures, brain damage, and limb amputations. A study of 25 college-age meningococcal survivors found that 3 had undergone amputations and 1 had extensive skin scarring — outcomes that reshape an entire life trajectory during what should be the most promising years of adulthood. For readers of this site who follow brain health closely, the neurological sequelae deserve specific attention. Bacterial meningitis triggers an aggressive inflammatory cascade within the central nervous system. The infection can cause cerebral edema, cortical necrosis, and damage to cranial nerves, particularly the eighth cranial nerve responsible for hearing.
Survivors may present with symptoms that overlap significantly with those seen in traumatic brain injury and early neurodegenerative conditions: impaired executive function, difficulty with memory consolidation, personality changes, and chronic fatigue. some require years of cognitive rehabilitation. The tragedy is compounded by the fact that these are young adults who had decades of healthy brain function ahead of them. However, it is important to note that not every case of meningococcal disease leads to severe neurological outcomes. Many patients recover fully, particularly when the infection is caught early and aggressive antibiotic treatment begins within hours. The problem is that meningococcal disease is notoriously difficult to identify in its early stages because initial symptoms — headache, fever, stiff neck — mimic the flu, a hangover, or the general malaise of college life. By the time the characteristic rash appears or a student becomes disoriented, the disease may have already progressed to a point where permanent damage is inevitable. Prevention through vaccination remains far more reliable than early detection in a population that is unlikely to rush to a doctor at the first sign of a headache.
Rising Case Counts Signal a Growing Threat
The trend lines are moving in the wrong direction. In 2024, the CDC reported 503 confirmed or probable meningococcal cases, the highest total since 2013. The year before, 2023 saw 422 cases, the highest since 2014. These numbers prompted the CDC to issue a Health Alert Network advisory specifically about the increase in invasive meningococcal disease, a step the agency reserves for situations it considers genuinely urgent. NBC News has reported that doctors are increasingly worried that fewer teens will get vaccinated even as case counts climb, a concern amplified by broader cultural skepticism toward vaccines. An estimated 100 to 125 cases of meningococcal meningitis occur annually on college campuses specifically, with 5 to 15 student deaths per year, according to the National Meningitis Association.
Those numbers have held relatively steady for years, but the overall rise in cases nationally suggests they could worsen — particularly if MenB vaccination rates remain stagnant or decline. The post-pandemic period has seen disruptions to routine adolescent vaccination schedules, and any decrease in baseline immunity creates conditions where outbreaks can gain a foothold more easily. What makes the current moment especially concerning is the convergence of rising cases with stalling public health infrastructure. Budget uncertainties at federal health agencies, shifting public attitudes toward vaccination, and the simple logistical challenge of reaching every 16-to-18-year-old before college enrollment all work against closing the MenB gap. Serogroup B does not care about policy debates. It exploits biological vulnerability, and right now, roughly 70 to 80 percent of college-bound students offer it exactly that.
What Parents and Students Should Actually Do Before Move-In Day
The practical question is straightforward: if your child has received the MenACWY vaccine but not the MenB vaccine, they are not fully protected against the type of meningitis most likely to circulate on a college campus. Both vaccines are needed. The American College Health Association issued updated immunization recommendations in April 2025 that include MenB guidance for college students, reflecting a growing consensus that the current two-tier system — one vaccine required, one merely suggested — is failing. The cost can be a barrier. MenB vaccines run between $190 and $280 per dose at retail, with Bexsero averaging around $273 and Trumenba around $271 per dose. The full series requires 2 to 3 doses depending on the product, meaning the out-of-pocket total can approach $550 to $840 without insurance.
However, most insurance plans do cover the vaccine, and the federal Vaccines for Children program covers eligible individuals age 18 and under at no cost. For uninsured students over 18, some college health centers offer the vaccine at reduced rates, and manufacturer patient assistance programs exist. The cost is real, but it is not insurmountable — and it is trivial compared to the cost of intensive care, rehabilitation, or a lifetime of managing neurological disability. The tradeoff parents should weigh is not “vaccine versus no vaccine” but rather “a few hundred dollars and two clinic visits versus even a small chance of catastrophic, irreversible harm.” Meningococcal disease is rare in absolute terms, which is precisely why some families deprioritize the MenB shot. But rarity at the population level is cold comfort when your student is the one in the ICU. The disease’s combination of low frequency and extreme severity is exactly the scenario vaccines were designed to address.
The Limitation of Mandates and the Problem of Awareness
Even where MenACWY mandates exist, enforcement varies. Some colleges accept philosophical or religious exemptions. Others allow students to sign waiver forms with minimal friction. And for MenB, which is only mandated in 2 states, the absence of a requirement effectively means the absence of a conversation. Pediatricians working under time pressure during annual well-visits may not bring up a vaccine that does not appear on the “required” list, and parents who are not specifically asking about meningitis B will not know to push for it. There is a subtler problem as well. The naming conventions confuse people.
Parents hear “meningitis vaccine” and assume it covers all forms of meningitis. They do not realize that MenACWY and MenB are different products targeting different bacterial serogroups. The medical system’s use of shorthand — “the meningitis shot” — inadvertently reinforces the misunderstanding that one vaccine does it all. Until physicians, school nurses, and college health administrators start explicitly distinguishing between the two, the MenB coverage gap will persist regardless of how many awareness campaigns run during National Meningitis Awareness Month. A warning for families navigating this: do not assume your student’s college requires MenB just because the enrollment health form mentions meningitis. Read the fine print. If the form references “meningococcal conjugate vaccine” or “MCV4,” that is MenACWY — not MenB. If there is no separate line item for “meningococcal serogroup B” or “MenB,” your student’s school is not requiring it, and you will need to seek it out independently.
Pentavalent Vaccines Could Change the Equation
Two new vaccines may finally collapse the two-shot problem into a simpler solution. Penbraya, manufactured by Pfizer, received FDA approval in October 2023 as the first pentavalent meningococcal vaccine, covering serogroups A, B, C, W, and Y in a single product for individuals ages 10 to 25. It is given as a two-dose series six months apart. In February 2025, the FDA approved Penmenvy from GSK as the second pentavalent option. Both vaccines eliminate the need for separate MenACWY and MenB series, which should reduce the logistical barriers and confusion that have kept MenB coverage so low.
The significance of these pentavalent vaccines cannot be overstated. If college mandates eventually adopt a single pentavalent requirement — one vaccine that covers all five serogroups — the MenB gap effectively disappears as a policy problem. The challenge now is uptake and integration into routine immunization schedules. New vaccines take time to appear in guidelines, insurance formularies, and clinic supply chains. But for parents making decisions today, asking a pediatrician about Penbraya or Penmenvy is a reasonable step that could simplify the path to full protection.
What the Future Holds for Meningitis Prevention on Campus
The next several years will likely determine whether the MenB gap narrows or widens. On one hand, the availability of pentavalent vaccines offers a genuine path to closing the coverage disparity. On the other hand, the broader cultural headwinds against vaccination, combined with funding uncertainty at the CDC and state health departments, could slow adoption. The April 2025 ACHA immunization guidelines represent forward movement, but guidelines without mandates have historically produced limited results for MenB. For the brain health community, the stakes are personal. Every case of meningococcal meningitis that results in cognitive impairment, seizure disorder, or hearing loss adds another person to the population living with acquired neurological disability.
These are not abstract statistics. They are former college freshmen who now navigate the world with damaged brains because a vaccine that existed was never administered. The path forward requires pediatricians to name the MenB vaccine explicitly, colleges to consider mandating it, and parents to ask for it by name. The vaccine exists. The data is clear. The only thing missing is the follow-through.
Conclusion
The meningitis vaccine that college students skip is the MenB vaccine, and the price of skipping it ranges from nothing — for the majority who will never encounter serogroup B — to everything, for the unlucky few who do. With MenB responsible for the majority of college meningococcal cases and every campus outbreak over nearly a decade, the gap between MenACWY coverage at 90 percent and MenB coverage below 30 percent represents one of the most consequential failures of health communication in adolescent medicine. The human cost — amputations, brain damage, death — is entirely preventable with a vaccine that has been available for years. If you are a parent, ask your child’s doctor specifically about the MenB vaccine or one of the newer pentavalent options like Penbraya or Penmenvy.
Do not assume the school-required meningitis vaccine covers serogroup B. If you are a college student reading this, check your own records. If you received only the MenACWY shot, talk to your campus health center about completing the MenB series. And if cost is the barrier, ask about insurance coverage or the Vaccines for Children program. The window for prevention is open, but meningococcal disease does not wait for convenient timing.
Frequently Asked Questions
What is the difference between MenACWY and MenB vaccines?
MenACWY protects against meningococcal serogroups A, C, W, and Y. MenB specifically targets serogroup B, which causes 63 to 67 percent of meningococcal cases among college-age students. They are completely separate vaccines targeting different bacterial strains, and receiving one does not protect against the serogroups covered by the other.
How much does the MenB vaccine cost without insurance?
MenB vaccines cost between $190 and $280 per dose at retail, with the full series requiring 2 to 3 doses depending on the product. Total out-of-pocket cost can range from roughly $380 to $840. However, most insurance plans cover the vaccine, and the federal Vaccines for Children program provides it free to eligible individuals 18 and under.
Can meningococcal meningitis cause permanent brain damage?
Yes. Up to 20 percent of survivors experience permanent complications, which can include seizures, hearing loss, cognitive impairment, and brain damage. The infection causes severe inflammation of the membranes surrounding the brain and spinal cord, and the resulting neurological damage can require years of rehabilitation.
Are meningitis cases increasing in the United States?
Yes. The CDC reported 503 confirmed or probable cases in 2024, the highest since 2013, and 422 cases in 2023, the highest since 2014. The agency issued a Health Alert Network advisory about the rise in invasive meningococcal disease.
What are the new pentavalent meningococcal vaccines?
Penbraya by Pfizer, approved in October 2023, and Penmenvy by GSK, approved in February 2025, are the first vaccines to cover all five meningococcal serogroups — A, B, C, W, and Y — in a single product. They eliminate the need for separate MenACWY and MenB vaccine series and are given as a 2-dose series.
Does my child’s college require the MenB vaccine?
Almost certainly not. Only 2 states mandate MenB vaccination for college entry, compared to 26 states that require MenACWY. If your child’s health form references “meningococcal conjugate vaccine” or “MCV4,” that covers only MenACWY. You will need to seek the MenB vaccine separately unless the form specifically names serogroup B.
